AUS
NZ
UK
CA
USA
IND
Healthcare
ASX Closes Lower as (ASX:AD8) Surges 26% and (ASX:BEN) Faces Sharp Decline
February 17, 2025 06:11 PM AEDT| By Team Kalkine MediaHighlights,(ASX:AD8) jumps 26% after strong half-year results,(,ASX:BEN,) slides 15% on weaker margins and earnings shortfall,Seven sectors end in the green, with Utilities leading gains,The Australian stock market wrapped up the trading session with...
Sonic Healthcare (ASX:SHL): A Closer Look at Stock Performance and Long-Term Outlook
February 17, 2025 04:17 PM AEDT| By Team Kalkine MediaHighlights,Sonic Healthcare (SHL) sees a 10% rise in,quarterly,share price.,Shareholder,return over the past three years shows a 23% decline.,Dividends contribute to a less negative total shareholder return (TSR) of -15%.,Sonic Healthcare (ASX:SHL),...
Recce Pharmaceuticals Shows Promising Results for Topical Gel in Treating Skin Infections, Sets Stage for Phase 3 Study
February 17, 2025 03:20 PM AEDT| By Team Kalkine MediaHighlights,Recce Pharmaceuticals’ Phase II clinical trial of its topical gel, RECCE 327 (R327G), achieved a 93% primary efficacy endpoint in treating Acute Bacterial Skin and Skin Structure Infections, including Diabetic Foot Infections.,The gel demo...
Recce Pharmaceuticals (ASX:RCE) Advances R327G to Phase III After Positive Phase II Trial Results
February 17, 2025 01:12 PM AEDT| By Team Kalkine MediaHighlights:,93% Efficacy Rate:,Recce Pharmaceuticals (ASX:RCE) reported that R327G achieved a 93% primary efficacy endpoint in its Phase II trial for bacterial skin infections.,Phase III Progress:,The company is moving forward with Phase III registra...
Althea Group’s Expansion into the North American THC Beverage Market
February 17, 2025 12:30 PM AEDT| By Team Kalkine MediaCannabis in a Can: Nanocap Althea Secures $4M to Boost THC Beverage Expansion in the US and Canada
Recce Pharmaceuticals (ASX:RCE) Advances ABSSSI Treatment with Positive Phase II Trial Results
February 17, 2025 11:30 AM AEDT| By Team Kalkine MediaBreakthrough in Infection Treatment: Recce Pharmaceuticals (ASX:RCE) Reports Strong Clinical Results
Health Check: After treating its final patient, Opthea anticipates the crucial outcomes of its make-or-break trial.
February 17, 2025 11:00 AM AEDT| By Team Kalkine MediaBiotech Developments and Market Movements in Focus
Imugene is well-funded and on the brink of revolutionizing cancer immunotherapy.
February 17, 2025 11:00 AM AEDT| By Team Kalkine MediaHighlights:,Imugene is advancing three immunotherapy programs focused on CAR-T therapies and oncolytic viruses.,The company secured new funding through convertible notes, supporting its ongoing clinical trials.,Development of allogeneic CAR-T therapi...
Will ASX:ARX Reinvent Its Course in a Rapidly Expanding Sector?
February 16, 2025 11:30 AM AEDT| By Team Kalkine MediaHighlights,ASX:ARX experienced a sharp decline in share price, erasing earlier gains.,The company’s price-to-sales ratio remains much lower compared to many peers in biotechnology.,Recent revenue performance shows steady growth, though it lags behind...
CSL's Earnings for the First Half of 2025: EPS Falls Short of Expectations
February 16, 2025 11:30 AM AEDT| By Team Kalkine MediaHighlights:,CSL Limited (ASX:CSL) reported an increase in revenue in its latest financial results.,Earnings per share came in below expectations despite stable profit margins.,The company's stock declined over the past week amid broader market moveme...
Can Imagion Biosystems Transform HER2 Imaging for Cancer Diagnostics?
February 16, 2025 11:00 AM AEDT| By Team Kalkine MediaHighlights,• MagSense HER2 imaging agent manufacturing commences for advanced clinical trials.,• Innovative imaging technology aims to enhance cancer diagnostics in the HER2+ breast cancer sector.,• Strategic steps underway to file an Investigational...
What Key Developments Define ASX:PME in Healthcare Imaging?
February 14, 2025 03:34 PM AEDT| By Team Kalkine MediaHighlights,Earnings per share growth has been robust.,Company leaders own a considerable portion of stock.,Governance practices and CEO compensation remain conservative.,The healthcare technology sector continues to evolve with advancements in diagno...
Avita Medical (ASX:AVH) Surges Over 11% on Strong Growth Outlook
February 14, 2025 02:21 PM AEDT| By Team Kalkine MediaHighlights,Avita Medical (AVH) shares,jump,over 11% following,revenue,guidance announcement.,Company,projects a 55-65% growth in,full-year,2024 commercial revenue.,Net loss widens due to increased operating expenses.,Avita Medical (ASX:AVH) saw a sha...
Healius Surges Amid Fresh Merger Talks with Australian Clinical Labs
February 14, 2025 01:47 PM AEDT| By Team Kalkine MediaHighlights,Healius,(,ASX:HLS,),emerges,as the top performer on the ASX 200 after reports of renewed merger discussions.,Australian Clinical Labs (ASX:ACL) also sees a slight uptick in share value.,Potential $2 billion deal gains attention following p...
Pro Medicus Gains Momentum as Analysts Raise Price Target
February 14, 2025 01:45 PM AEDT| By Team Kalkine MediaHighlights,Pro Medicus (PME) receives an upgraded outlook with a higher price target.,Shares recover after a dip following,first,-half earnings results.,Analyst boosts the target price by 18%, reflecting strong long-term prospects.,Pro Medicus (ASX:P...
Imugene's (ASX:IMU) Azer-cel Trial Shows Strong 57% Complete Response Rate in Lymphoma Patients
February 14, 2025 01:41 PM AEDT| By Team Kalkine MediaHighlights,Promising Trial Data:,Azer-cel achieves a,57% complete response rate,in relapsed lymphoma patients.,Enhanced Immune Response:,The addition of IL-2 boosts T-cell proliferation, aiding patient recovery.,Long-Lasting Remissions:,Some patients...
Sonic Healthcare and Brambles: Stocks to Watch for Growth and Stability
February 14, 2025 12:08 PM AEDT| By Team Kalkine MediaHighlights,(SHL),has seen a 9.4% dip in 2024 but,remains,a key player in global pathology services.,(BXB),is near its 52-week high,,benefiting,from its strong,logistics,and pallet rental business.,Both companies,exhibit,unique strengths, making them...
AVITA Medical Soars 10% on Revenue Growth and Optimistic Outlook
February 14, 2025 11:50 AM AEDT| By Team Kalkine MediaHighlights,Revenue Surge:,AVITA Medical reports a 30% increase in Q4 commercial revenue, reaching US$18.4 million, with full-year revenue up 29% to US$64 million.,Profitability in Sight:,Despite a net loss of US$61.8 million, management forecasts fre...
Cochlear Shares Plunge 10% on Friday, Here's Why.
February 14, 2025 11:40 AM AEDT| By Team Kalkine MediaHighlights,Revenue Growth:,Sales revenue rose 5% to $1.17 billion, driven by implant and acoustics sales.,Services Weakness:,Revenue from the Services segment fell 13%, dragging down overall performance.,Lowered Profit Outlook:,Full-year net profit e...
Analysts Underestimate Pro Medicus' (ASX:PME) Potential Amidst Strong Results
February 13, 2025 07:40 PM AEDT| By Team Kalkine MediaHighlights,Pro Medicus (ASX:PME) reports impressive half-year profit growth.,New contract wins are expected to accelerate future revenues.,Analysts’ expectations did not align with the company’s strong performance.,Despite reporting a substantial 42....
Advertise your brand on Kalkine Media